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Abstract
Colorectal cancer (CRC) is one of the most frequent and lethal cancer types
worldwide. While surgery with chemotherapy and radiotherapy remains the only
curative approach for localized CRC, for metastatic disease the therapeutic land-
scape has significantly evolved over the last years. Development and approval of
novel targeted therapies, such as monoclonal antibodies against EGFR and VEGF,
have significantly increased the median survival of patients with metastatic disease,
with some trials reporting a benefit over 40 months. Increasing accessibility of high
throughput sequencing has unraveled several new therapeutic targets. Actionable
alterations, such as HER2 overexpression, BRAF mutations, and NTRK fusions,
are currently available in metastatic disease, providing significant therapeutic
opportunities for these patients, while new emerging agents, as immune
checkpoint inhibitors, promise better treatment options in the near future. In this
chapter, an overview of established and future CRC targeted therapies in the clinical
setting is provided, as well as their mechanism of action, limitations, and future
applicability.
Keywords: EGFR, immunotherapy, metastatic colorectal cancer, targeted therapy,
VEGF
1. Introduction
Colorectal cancer is the third most common cancer worldwide and remains an
important cause of death. CRC diagnosis and treatment require a multidisciplinary
approach, and in stage IV disease combination chemotherapy (CT) and regional
multimodality treatments  like metastasectomy and other local treatments  are
increasingly used. Systemic therapy has evolved over the past few decades, with the
emergence of combination CT and targeted agents (Figure 1).
In the present review, genomic and tumor microenvironment alterations driving
treatment selection are discussed.
1
1.1 Historical background
Metastatic CRC (mCRC) presents with synchronous metastatic disease at initial
diagnosis in 20% of cases, with 50–60% of patients developing metachronous
metastases. Approximately 56% of patients with CRC will ultimately die from their
cancer [1]. The cornerstone of CRC treatment for 20 years has been
fluoropyrimidine-based CT doublets, with either irinotecan (FOLFIRI or CAPIRI)
or oxaliplatin (FOLFOX or CAPOX) in the first- and second-line settings [2].
In the past two decades, remarkable progress has been achieved in mCRC treat-
ment with the introduction of molecular targeted agents (Figure 2). Today, the
median overall survival (OS) for these patients in phase III trials is approximately
30 months, more than doubling that of 20 years ago [3]. Simultaneously, mortality
has declined, what is attributed to earlier diagnosis (due to screening tests) and
improved treatment options, including new systemic CT agents and biologic agents
targeting specific pathways [1].
More recently, consensus molecular subtypes (CMS) defined by gene expression
profiling have identified biologically different CRC subtypes, which seem to have a
prognostic and predictive value. However, CMS subtyping is not a standard test with
therapeutic application at present, being more relevant in the research field [2].
2. EGFR pathway
New targeted therapies against the epidermal growth factor receptor (EGFR)
had an impressive impact on mCRC prognosis, with an actual median OS over
30 months (varying according to therapeutics options) [4–6].
As part of the ErbB tyrosine kinase family, EGFR is a transmembrane receptor
and its activation by extracellular ligands stimulates downstream pathways, such as
Figure 1.
Targeted therapies that have been approved or are currently under investigation for advanced colorectal cancer.
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RAS–RAF–MEK-MAPK, PIK3CA-AKT, the SRC family kinases, PLCγ-PKC, and
JAK/STATs, inducing proliferation, migration, invasion, survival, and angiogenesis
[6, 7]. Thus, EGFR is an important factor in tumor development and progression,
being expressed in various cancers and in 60–80% of CRCs [8].
Target therapy against EGFR is now a standard of care in RAS wild-type mCRC.
Two monoclonal antibodies (mAbs) are approved: cetuximab (human-mouse chi-
meric mAb) and panitumumab (fully human mAb). By recognizing and binding to
the extracellular domain of the EGFR receptor, these mAbs prevent binding of
other extracellular ligands and subsequent receptor internalization and degradation,
thus inhibiting and blocking downstream pathways and signaling [9]. Tumor RAS
mutational status predicts efficacy of anti-EGFR agents in mCRC patients, with
RAS mutations being a well-established negative predictive biomarker for patient
selection [10].
2.1 Clinical trials
Several phase II and III clinical trials have established the efficacy of cetuximab
and panitumumab, either in monotherapy or in association with CT, in terms of
progression-free survival (PFS), OS, and overall response rate (RR), while
maintaining quality of life (Table 1) [6, 11–13].
2.1.1 First-line setting
The PRIME trial, a randomized phase III trial investigating the addition of
panitumumab to FOLFOX4 as first-line therapy in RAS wild-type mCRC, showed a
2- and 6-month PFS and OS benefit, respectively, with the combination. Regarding
safety, known EGFR inhibition adverse events (AE) were more frequently observed
with panitumumab, including skin toxicity and diarrhea (36% vs. 2% and 18% vs.
9% in panitumumab and placebo arms, respectively) [11].
The randomized phase II PEAK trial compared the efficacy and safety of
mFOLFOX6 plus panitumumab with mFOLFOX plus bevacizumab (an anti- vas-
cular endothelial growth factor [VEGF] mAb) as first-line therapy in RAS wild-type
mCRC. The study primary endpoint was met, with panitumumab showing a 3.5-
month PFS increase compared with bevacizumab. An OS improvement was also
Figure 2.
Timeline of development of targeted therapies in colon cancer.
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observed, although not statistically significant [14]. Rivera et al. and Stintzing S
et al. also demonstrated that early tumor shrinkage in an important and early
predictor of treatment sensitivity and deep tumor response correlates with OS
[15, 16].
The open-label phase II PLANET-TTD trial compared panitumumab with two
different CT regimens (FOLFOX 4 and FOLFIRI) as first-line treatment of RAS
wild-type mCRC, but no significant efficacy differences were observed between the
two regimens [17].
The 314 trial, a single-arm phase II study evaluating first-line panitumumab plus
FOLFIRI in mCRC patients, confirmed the impact of KRAS exon 2 status in being a
negative predictor of efficacy in mutant patients. In a total of 154 patients, 59% had
KRAS wild-type tumors. RR and median duration of response (DoR) were higher in
the KRAS wild-type group. Additionally, more patients in the wild-type group
underwent R0 resection (8% vs. 5%), and a PFS benefit was also observed in this
group (8.9 vs. 7.2 months) [18].
In the COIN trial, cetuximab was added to oxaliplatin-containing CT (FOLFOX
or CAPOX) in first-line setting of mCRC. In patients with KRAS wild-type tumors,
no OS or PFS difference was reported between the two groups, while overall
response rate (ORR) was higher with the addition of cetuximab to CT compared to
CT alone [19].
Similar ORR results were seen in the OPUS trial. In KRAS wild-type tumors, the
addition of cetuximab to FOLFOX-4 was associated with a clinically significant
increased chance of response and a lower risk of disease progression. The same
results were not seen in the overall population, confirming the relevance of KRAS
mutational status [12].
Although the addition of cetuximab to oxaliplatin-containing CT had little
survival impact, the CRYSTAL trial showed different results when combining
cetuximab to FOLFIRI. A borderline significant PFS increase was seen in the
combination arm, although with no OS differences. However, when KRAS
mutational status was considered, a significant PFS increase was observed favoring
cetuximab [20].
Additionally, in the phase III open-label FIRE-3 trial, cetuximab was compared
with bevacizumab, both in combination with FOLFIRI. No differences were
observed in the primary endpoint of ORR or in PFS, but the median OS was
improved in cetuximab arm [21].
Cetuximab was further compared with bevacizumab, both combined with CT
(FOLFOX or FOLFIRI), in the CALGB 80405, with no significant differences in
ORR, PFS, or OS [22].
2.1.2 Second- and subsequent-line setting
In the 181 trial, the efficacy and safety of adding panitumumab to FOLFIRI was
compared with FOLFIRI alone in RAS wild-type mCRC patients who had failed the
initial treatment. Addition of panitumumab to the regimen resulted in a significant
PFS improvement, of approximately 2 months. Although not significant, a trend
towards an OS benefit was seen with the addition of panitumumab [23].
Conversely, the randomized open-label PICOLLO trial reported no benefit with
the addition of panitumumab to irinotecan after progression on fluoropyrimidine,
with or without oxaliplatin. However, better PFS and more responses were reported
in the panitumumab group [24].
In 2004, Saltz et al. and Cunningham et al. evidenced the role of cetuximab in
heavily pretreated patients. Saltz et al. reported a median OS of 6.4 months and a
median PFS of 1.4 months in 57 patients receiving cetuximab monotherapy after
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progression on irinotecan, and a tumor RR of 8.8% [25]. Cunningham et al. included
over 300 patients and investigated the role of cetuximab (with or without
irinotecan) after progression on irinotecan. A PFS and ORR benefit was observed,
with a numeric but not statistically significant difference also observed in OS (8.6
vs. 6.9 months) [26].
Later, the randomized phase II ASPECCT trial compared panitumumab alone
with cetuximab alone as third-line treatment for mCRC patients with RAS wild-
type (exon 2) tumors. With OS as primary endpoint, panitumumab was given at a
dose of 6 mg/Kg every two weeks and cetuximab at a loading dose of 400 mg/m2,
followed by a weekly dose of 250 mg/m2. No efficacy differences were observed,
with a median OS of 10.4 months for panitumumab and 10.0 months for
cetuximab [27].
Setting Study Treatment RR□, % PFS□, months OS□,
months
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BEVA, bevacizumab; CET, cetuximab; CPT-11, irinotecan; mt, mutated; NR, not reported; ORR, overall response
rate; OS, overall survival; OXAL, oxaliplatin-containing chemotherapy regimen; PAN, panitumumab; PFS,
progression-free survival; wt, wild-type.
□Results for the KRAS wild-type subgroup, except if clearly stated.
*Difference between groups is statistically significant (p < 0.05).
Table 1.
Targeted therapies against EGFR in colorectal cancer.
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2.1.3 Maintenance/treatment intensification
Regarding maintenance and treatment intensification, three clinical trials are
worth mentioning: VOLFI, VALENTINO, and SAPPHIRE.
VOLFI was a randomized open-label phase II trial comparing the addition of
panitumumab to FOLFOXIRI CT regimen. An ORR of 87,3%was seen in the
FOLFOXIRI plus panitumumab arm, which was higher compared with FOLFOXIRI
alone. PFS was similar in both arms, whereas OS showed a trend in favor of
panitumumab [28]. This was the highest ORR reported inmCRC, suggesting that these
protocols can be considered to obtain maximum cytoreduction in selected patients.
The VALENTINO trial, an open-label phase II trial, investigated maintenance
therapy with panitumumab (induction therapy with FOLFOX-4 + panitumumab
followed by maintenance with panitumumab 5FU/LV). The study hypothesis that
panitumumab alone was not inferior to the combination as maintenance therapy
could not be proven. ORR and OS results did not differ between the two arms [29].
In the SAPPHIRE trial, patients received six cycles of mFOLFOX6 plus
panitumumab as induction therapy. Patients who completed induction therapy with-
out progressionwere then randomized tomFOLFOX6plus panitumumab (groupA) or
5-FU/LV plus panitumumab (group B). PFS, RR, OS, and time to treatment failure
were similar between groups, adding to the concept that planned discontinuation of
oxaliplatin after six cycles of mFOLFOX6 is a potential treatment option for mCRC
patients, achieving similar efficacy while reducing oxaliplatin-associated peripheral
neuropathy compared with mFOLFOX6 plus panitumumab [30].
2.2 Resistance mechanisms
Although anti-EGFR therapy has shown benefit in a particular subgroup of CRC
patients, primary or innate resistance is high among unselected patients. Further-
more, even patients that initially respond to cetuximab and panitumumab, eventu-
ally develop resistance and relapse under these therapies (secondary resistance).
Knowledge of the resistance mechanisms associated with the EGFR pathway is
crucial to improve therapy efficacy.
2.2.1 RAS-RAF mutations
RAS–RAF-MAPK is an EGFR direct downstream signaling pathway, highly
deregulated in CRC. Mutations frequently found in these family members generally
lead to protein constitutive activation independently of the upstream signaling
cascade. Over the last decade, analysis of retrospective clinical trial data (in partic-
ular of the OPUS, CRISTAL, and PRIME trials) led to the discovery that patients
harboring RAS (KRAS and NRAS) and BRAF (specially V600E) activating muta-
tions do not benefit from cetuximab and panitumumab treatment, and that it could
even be detrimental for them [31]. These results have led the European Medicines
Agency (EMA) and Food and Drug Administration (FDA) to recommend against
the use of EGFR-targeted therapies in patients harboring RAS and BRAFmutations.
These mutations are currently the only clinically validated predictive marker of
resistance to anti-EGFR therapies in CRC.
2.2.2 PIK3CA gene and PTEN expression
Although RAS and RAF mutations are effective in predicting resistance, not all
wild-type patients respond to cetuximab and panitumumab. The EGFR receptor
also signals through the PI3K-AKT pathway, resulting in tumor cell proliferation
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and survival [32]. Retrospective studies of cetuximab treatment in chemorefractory
metastatic CRC patients revealed that KRAS wild-type patients with PIK3CA muta-
tions in exon 20 (but not in exon 9) have lower response rates compared to
unmutated patients (0.0% vs. 36.8%; 95% confidence interval [CI] 0.00–0.89;
p = 0.029) [33]. PTEN is another potential marker of response to anti-EGFR ther-
apy, given its inhibitory role on PI3K-AKT signaling pathway. Although PTEN
studies are scarce and inconclusive, some works suggest that loss of PTEN expres-
sion (measured by immunohistochemistry [IHC]) is associated with decreased RR,
PFS, and OS in metastatic CRC patients treated with anti-EGFR therapy [34, 35].
2.2.3 Other resistance pathways
Evidence from cellular studies has suggested that constitutive activation of other
EGFR downstream pathways, such as those including the JAK–STAT family, are
implicated in resistance to the anti-EGFR gefitinib [36, 37].
Additionally, amplification of other receptor tyrosine kinases (RTKs) has been
proposed as a resistance mechanism to anti-EGFR therapies. Expression of VEGF-1 or
its receptor (VEGFR) has been associated with cetuximab resistance in both preclin-
ical models and metastatic CRC patients [38]. Bertotti et al. reported that human
epidermal growth factor receptor 2 (HER2) gene amplification correlated with
cetuximab resistance in a patient-derived xenograft mouse model [39]. Besides
HER2, also HER3 has been described to have a role in resistance mechanism to EGFR-
targeted therapies. In a cohort of metastatic CRC patients treated with irinotecan and
cetuximab, HER3 overexpression was associated with lower PFS and OS [40].
Finally, growing evidence implicates the MET pathway in both primary and sec-
ondary resistance mechanisms to mAbs in KRAS wild-type patients, through MET
amplification or hepatocyte growth factor (HGF) increased expression [41]. In a
randomized phase II clinical trial of chemorefractory KRAS wild-type anti-EGFR-
naïve patients, the combination of anti-HGFmAbs and panitumumab led to higher RR
and a trend towards better outcomes in the population withMET overexpression [42].
2.3 BRAF
Although RAS mutations are negative predictors of efficacy in cetuximab and
panitumumab treatment, it is acknowledged that not all RAS wild-type patients
respond to these agents. To investigate this, research efforts were driven downwards
in the MAPK pathway, putting the spotlight on BRAF. This is the main effector in
EGFR pathway and is usually mutated in 5–10% of mCRC patients. BRAF and KRAS
are usually mutually exclusive, with BRAF V600E mutation (class I) accounting for
most alterations found and conferring worse prognosis to these patients.
Regardless of EGFR blockade, BRAF mutations can keep the downstream sig-
naling persistently activated, suggesting that they can confer EGFR blockade resis-
tance. In fact, in a retrospective trial, De Roock et al. showed that chemorefractory
mCRC patients with BRAF V600E mutations have significantly lower RR to
cetuximab than patients with wild-type tumors (8.3% vs. 38.0%; odds ratio 0.15;
p = 0.0012) [43]. Several multicentre trials and meta-analyses have subsequently
confirmed that BRAF V600E mutation results in shorter PFS and OS compared to
the wild-type phenotype, emphasizing its role in resistance to anti-EGFRs in
patients with chemorefractory mCRC.
Multiple combinations with drugs targeting the MAPK pathway have been
tested in BRAF-mutant CRC. Monotherapy results were disappointing when com-
pared to the clinical activity seen in melanoma. In contrast to melanoma, CRC
expresses high levels of activated EGFR, which reactivate the MAPK pathway after
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single BRAF inhibition [44, 45]. In view of the possibility of therapy resistance via
EGFR signaling feedback activation, the trial was amended to include safety and
efficacy assessment of vemurafenib combined with cetuximab in a heavily
pretreated population, with positive results (median PFS of 3.7 months and median
OS of 7.1 months). Similar results were observed when combining dabrafenib with
panitumumab (median PFS of 3.5 months) and encorafenib with cetuximab (RR of
23.1%, median PFS of 3.7 months), with phase II results of the latter showing a
median PFS of 4.2 months and an ORR of 22% [46].
CT was also combined with BRAF and EGFR inhibition in a phase II trial of
irinotecan, cetuximab, and vemurafenib. A total of 106 patients were enrolled, with
the study reporting a PFS benefit of 4.3 months with the addition of vemurafenib
compared to 2.0 months in the control arm [47].
BRAF inhibition can also induce EGFR overactivation or PI3K modulation, and
triplet combos targeting EGFR, MAPK, and PI3K have shown positive results. The
MEK116833 trial included 24 patients receiving full-dose combination of
panitumumab, trametinib, and dabrafenib and reported an ORR of 21%, a median
PFS of 4.1 months, and an OS of 9.1 months. Additionally, a randomized phase II
trial combining encorafenib, cetuximab, and the PI3K inhibitor alpelisib reported a
median PFS of 5.4 months and an ORR of 27% in interim analysis [48–51].
More recently, the phase 3 BEACON trial investigated the doublet of encorafenib
plus cetuximab and the triplet of encorafenib plus cetuximab plus binimetinib in
patients with BRAF-mutant CRC after one or two prior regimens. The updated anal-
ysis confirmed an ORR of 27% with the triplet versus 20% with the doublet versus 2%
in the control arm. Median OS was 9.3 months with the duplet and 5.9 months in the
control group (hazard ratio [HR] 0.61). The benefit was seen across all subgroups.
Numerically identical median OS was observed when comparing the triplet and dou-
blet, with higher toxicity for the triplet (mainly gastrointestinal toxicity and anemia).
Subgroup analysis suggested survival benefits in some subgroups, such as those with
ECOG 1, three or more organs affected, and higher levels of C-reactive protein and
with unresected primary tumors, suggesting that patients with higher disease burden
and inflammatory drive could benefit from triple therapy. PFS was also comparable
between doublet and triplet and clearly superior to the control arm [52, 53].
2.4 HER2-amplified CRC
HER2 is a growth factor receptor involved in CRC development and progression.
HER2 amplification is relatively uncommon, reported in only 3–5% of metastatic
CRC patients with wild-type KRAS and wild-type BRAF [54].
Trastuzumab is a monoclonal antibody targeting HER2. The phase II HERACLES
trial included mCRC patients with KRAS wild-type, HER2-positive (defined as
2+/ 3+ HER2 score in >50% of cells by IHC or HER2:CEP17 ratio > 2 in >50% of cells
by fluorescent in situ hybridization [FISH]) tumors who were refractory to standard
therapy with EGFR inhibitors and were treated with trastuzumab and lapatinib.
ORR was 30%, with one complete response, and median OS was 46 weeks [55]. The
most common AEs were diarrhea, rash, and fatigue (78%, 48%, and 48%, respec-
tively). These findings suggested that HER2 positivity was an important driver in
CRC. In the phase IIa multi-basket MYPATHWAY trial, patients with HER2-
amplified tumors (including CRC) received dual blockade therapy with
pertuzumab and trastuzumab. Preliminary results showed promising response, with
an ORR of 37.5%, and suggested durable responses with HER2-targeting agents,
with a median DoR of 11 months [56].
Both the TRIUMPH (trastuzumab and pertuzumab) and MOUNTAINEER
(trastuzumab and tucatinib) trials reported high response rates (35% and 52%,
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respectively) and encouraging median PFS (4.0 and 8.1 months, respectively),
supporting dual HER2 blockade in patients with HER2-amplified metastatic CRC
[57, 58]. Conversely, the combination of pertuzumab and TDM-1 did not show an
enhanced objective response in the HERACLES-B trial, although achieving a similar
disease control to the HERACLES-A trial (ORR of 10% and median PFS of
4.8 months at cut-off) [59].
Regarding new antibody-drug conjugates, the phase 2 DESTINY-CRC01 trial, of
trastuzumab deruxtecan (T-DXd; DS-8201) and also in patients with metastatic
HER2-amplified CRC, reported significant responses (ORR of 45.3%, disease
control rate [DCR] of 83%), including in patients previously submitted to HER2
blockade [60].
3. VEGF pathway
Tumor angiogenesis is one of the hallmarks of cancer and a key process in tumor
development [61, 62]. One of the most relevant pathways involved in angiogenesis
is the vascular endothelial growth factor/vascular endothelial growth factor recep-
tor (VEGF/VEGFR) signaling pathway. VEGF-A is a heparin-binding glycoprotein
with potent angiogenic activity. VEGF is produced by different cell types, such as
immune cells, fibroblasts, and cancer cells, in response to tumor hypoxia via
hypoxia-inducible factor (HIF)-1a pathway, inducing an angiogenic switch [63].
Overproduction of pro-angiogenic growth factors leads to formation of chaotic
blood vessels in the tumor, with a leaky endothelial wall [64].
3.1 VEGF inhibition in mCRC
In CRC, primary tumor growth and distant metastases development are highly
dependent on new vessel formation, making VEGF signaling pathway an attractive
therapeutic target. Inhibition of VEGF signaling pathway can be achieved through
neutralizing antibodies binding VEGF ligands or blocking VEGFR, or tyrosine
kinase inhibitors (TKIs) blocking intracellular VEGFR-dependent signaling [65].
Bevacizumab. The first angiogenesis inhibitor approved for mCRC was
bevacizumab, an immunoglobulin G (IgG)1 monoclonal antibody with affinity to
VEGF-A. Several trials have evaluated the benefit of adding bevacizumab to cyto-
toxic regimens as first-line treatment of patients with mCRC, with inconsistent PFS
and OS results (Table 2).
A phase III trial conducted by Hurwitz et al. compared the efficacy of irinotecan,
bolus fluorouracil, and leucovorin (IFL) plus bevacizumab versus IFL plus placebo
in untreated mCRC patients. Bevacizumab was intravenously administered at a
dose of 5 mg/kg every two weeks along with CT. Bevacizumab arm showed a
meaningful improvement in OS (20.3 versus 15.6 months in placebo arm) and PFS
(10.6 versus 6.2 months in placebo arm) [66]. Saltz et al. assigned mCRC patients in
a 2x2 factorial design to receive CAPOX or FOLFOX4 followed by bevacizumab or
placebo as first-line treatment. Median PFS was higher in the bevacizumab group
compared with placebo (9.4 versus 8.0 months). OS differences did not reach
statistical significance, but only 29% of bevacizumab recipients were treated until
disease progression or toxicity [67]. For elderly patients with untreated and
unresectable mCRC not candidates for oxaliplatin- or irinotecan-based therapies,
the phase III AVEX trial compared the efficacy and safety of capecitabine combined
with bevacizumab versus capecitabine alone. Capecitabine was given at a dose of
1000 mg/m2 orally twice a day on days 1–14 and bevacizumab was administered
intravenously at a dose of 7.5 mg/kg on day 1, every 21 days. Longer PFS was
9
Landscape of Current Targeted Therapies for Advanced Colorectal Cancer
DOI: http://dx.doi.org/10.5772/intechopen.93978
documented in the bevacizumab arm (9.1 versus 5.1 months for capecitabine
alone), with acceptable tolerance. Grade ≥ 3 adverse events reported in the combi-
nation arm included hand-foot syndrome (16%), diarrhea (7%), and venous
thromboembolic events (8%) [68].
Despite these results, the 2015 phase III ITACa trial reported no statistically
significant PFS and OS differences when bevacizumab was added to standard first-
line CT (FOLFIRI or FOLFOX4) [69]. Other previous trials reported the same
negative results. Considering these discrepancies, a 2017 meta-analysis based on 9
studies examined the survival impact of bevacizumab plus CT in first-line treat-
ment of mCRC patients, showing that the combination significantly prolonged PFS
(HR 0.66; p < 0.0001) and OS (HR 0.84; p = 0.0001) compared with CT alone.
Subgroup analyses suggested that irinotecan-based regimens might be a better
partner for bevacizumab than oxaliplatin-based regimens, with superior PFS and
OS benefit [70].
Sidedness of the primary tumor is known to be an important prognostic factor in
metastatic setting of CRC, with worst survival outcomes for right-sided tumors.
Several clinical trials investigated the prognostic role of bevacizumab in the treat-
ment of patients with right-sided and left-sided CRC. A post-hoc analysis of 16
randomized trials including PEAK, FIRE-3, and CALGB/SWOG trials showed that
right-sided tumors have impaired CT sensitivity, while addition of bevacizumab to
cytotoxic regimens can be an optimal first-line treatment for RAS-wild-type right-
sided mCRC [71].
Although continuing bevacizumab with second-line chemotherapy showed ben-
efit after disease progression, other anti-VEGF drugs should be considered for fast
progressors (PFS <3–4 months) [72].
In patients with unresectable mCRC who are not candidates for intensive ther-
apy, the ongoing phase III SOLSTICE trial is currently comparing trifluridine/
tipiracil (TAS-102) plus bevacizumab versus capecitabine plus bevacizumab as
first-line treatment [73].
Aflibercept. Aflibercept is a recombinant fusion protein composed by VEGF-
binding portions from VEGFR-1 and -2 extracellular domains fused to the Fc por-
tion of human IgG1. It acts by blocking the activity of VEGF-A and -B, preventing
their binding to VEGFR on endothelial and tumor cells [74].
The role of aflibercept was evaluated in the phase III VELOUR trial, of mCRC
patients previously treated with oxaliplatin-based regimens in first line, including
with bevacizumab. Second-line FOLFIRI was intravenously administered with pla-
cebo or aflibercept at the dose of 4 mg/kg every two weeks. Aflibercept improved
the median OS (13.50 vs. 12.06 months) and median PFS (6.90 versus 4.67 months)
compared to placebo [74]. These results lead to approval of the drug in combination
with FOLFIRI as second-line treatment for patients pretreated with oxaliplatin-
based doublet with bevacizumab. The most common grade ≥ 3 AEs reported in the
VELOUR trial included neutropenia, diarrhea, stomatitis, hypertension, and
fatigue. Additionally, there was no evidence of greater toxicity in patients previ-
ously treated with bevacizumab [74].
More recently, the phase II AFFIRM trial investigated the addition of aflibercept
to first-line oxaliplatin-based regimens in mCRC patients. Patients received
mFOLFOX6 plus aflibercept or mFOLFOX6 alone. Despite VELOUR results, this
study did not reach the primary endpoint of PFS. Adding aflibercept to first-line
mFOLFOX6 did not increase efficacy and was associated with higher toxicity [75].
Ramucirumab. Ramucirumab is a human IgG1 monoclonal antibody against
VEGFR-2. Efficacy and safety of ramucirumab in combination with second-line
FOLFIRI was evaluated in the phase III RAISE trial. Patients with progressive mCRC
during or after first-line treatment with bevacizumab, oxaliplatin, and
10
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fluoropyrimidine were randomized to receive intravenous ramucirumab 8 mg/kg plus
FOLFIRI or placebo plus FOLFIRI every 2 weeks. Ramucirumab significantly
improved survival in this subpopulation, reaching amedian OS of 13.3 months, against
11.7 months in the placebo arm. Grade ≥ 3 AEs included neutropenia (38%), hyper-
tension (11%), diarrhea (11%), and fatigue (12%). Febrile neutropenia was only
reported in 3% of patients and most toxicities reported were manageable [76]. This
trial lead to the approval of ramucirumab in combination with FOLFIRI in the second-
line setting of mCRC previously treated with bevacizumab, oxaliplatin, and
fluoropyrimidine in first line.
Regorafenib. The only TKI approved for mCRC treatment is regorafenib, a
multi-kinase inhibitor of angiogenic pathway members, including VEGFR-1 and -2,
platelet-derived growth factor receptor (PDGFR)-β, and tyrosine kinase with
immunoglobulin-like and EGF-like domains 2 (TIE2) [77].
Several phase III trials evaluated the role and efficacy of regorafenib as single-
agent in mCRC patients progressing after several standard lines of treatment
(Table 2). The CORRECT trial was the first to compare treatment with regorafenib
160 mg daily for 21 days, every 28-day cycle, versus placebo. Final study results
reported a quality of life (QoL) and OS (6.4 vs. 5.0 months in placebo arm)
improvement in favor of regorafenib [78]. The phase III CONCOUR trial was similar
to the CORRECT trial but exclusively recruited Asian patients, holding similar OS
results [79]. The CONSIGN trial was designed to specifically evaluate regorafenib
safety. In a total of 2864 patients (median age of 62 years), the most common
grade ≥ 3 AEs were hypertension (15%), hand-foot syndrome (14%), fatigue (13%)
and diarrhea (5%). Grade ≥ 3 laboratory toxicities included elevated alanine
aminotransferase (6%), aspartate aminotransferase (7%), and bilirubin (13%) [80].
3.2 Resistance to anti-VEGF drugs
Despite the outcome benefits seen with anti-VEGF agents in CRC, these are usually
transient and followed by relapse and tumor growth [81]. Several resistance mecha-
nisms to anti-VEGF therapies have been described, including VEGF axis-dependent
alterations, non-VEGF axis-dependent upregulation, and stromal cell interactions [82].
3.2.1 VEGF-dependent pathways
Upregulation of alternative VEGFR-2 angiogenic ligands, such as VEGF-C, D,
and placental growth factor (PIGF), can bypass VEGF-A inhibition and elicit
bevacizumab resistance [82]. In a phase II trial, Kopetz et al. showed that PlGF,
VEGF-C, and VEGF-D plasma levels in mCRC patients receiving FOLFIRI plus
bevacizumab were elevated prior to and at the time of disease progression [83].
3.2.2 Non-VEGF-dependent pathways
Complementary angiogenic pathways other than VEGF/VEGFR signaling exert
control on tumor angiogenesis and may explain acquired resistance to anti-VEGF
therapies. These pathways involve members of the platelet-derived growth factor
(PDGF) family, HIF, members of the fibroblast growth factor (FGF) family,
angiopoietin (Ang), and Notch [84, 85].
The PDGF family consists of five ligands that bind to tyrosine kinases PDGFR-α
and -β, activating downstream signal transduction pathways, as PI3K/Akt and
PLCγ. PDGF-C was shown to be upregulated in cancer-associated fibroblasts
(CAFs) of anti-VEGF-resistant tumors in vivo [86], making it a possible resistance
mediator.
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HIF-1 is a transcription factor with a key role in cellular response to reduced
oxygen levels. Among its multiple downstream effects is induction of VEGF-A,
VEGFR, PIGF, and PDGF expression [85].
Growth factors of the FGF family are potent mediators of tumor angiogenesis.
Binding of FGF to fibroblast growth factor receptor (FGFR) tyrosine kinase acti-
vates downstream pathways such as MAPK/ERK, PI3K/Akt, and STAT [86], acting
synergistically with VEGFA to induce angiogenesis via endothelial cell proliferation,
survival, and migration [87]. FGF-2 upregulation is observed in anti-VEGF-
resistant tumors, especially in tumors exposed to a hypoxic environment, [86] while
FGF-2 blockade results in decreased tumor growth in in vivo models [88].
Ang-Tie signaling is a vascular-specific pathway essential for blood vessel devel-
opment and vascular permeability regulation. Ang-2 acts as an antagonist of the Tie2
receptor, leading to development of vascular sprouts in the context of VEGF exposure
[86]. mCRC patients with poor bevacizumab response showed high serum Ang2
levels, suggesting its relevance in resistance to anti-angiogenic therapy [89].
Delta-like ligand 4 (DII4) is a Notch ligand overexpressed in several solid
malignancies, including CRC. DII4 upregulation is thought to contribute to
Study Treatment PFS, months OS, months HR (p-value)






PFS - 0.54 (<0.001)












PFS - 0.83 (0.002)





















































OS - 0.55 (<0.001)
CONSIGN (III) Regorafenib AEs: hypertension (15%), hand-foot skin reaction
(14%), fatigue (13%), diarrhea (5%), and
elevated aminotransferase (6%), aspartate
aminotransferase (7%), and bilirubin (13%).
AEs, adverse events; BEVA, bevacizumab; CAP, capecitabine; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
*Difference between groups is statistically significant (p < 0.05).
Table 2.
Targeted therapies against VEGF in colorectal cancer.
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bevacizumab resistance, which can be overcome by Notch inhibition with a γ-
secretase inhibitor [90].
TGF-β is a ligand for type II TGF-β receptors and endoglin (CD105). It has
important regulatory functions in angiogenesis, either directly, or indirectly by
activating fibroblasts to produce extracellular matrix and stimulating the tube for-
mation in endothelial cells [91]. Anti-VEGF therapy-resistant tumors can exhibit
high levels of TGF-β1 expression. Additionally, in preclinical models VEGF pathway
blockade led to increased CD105 levels, suggesting a role for CD105 in anti-VEGF
therapy resistance [92].
3.2.3 Stromal cell interactions
It has been recently suggested that tumor stromal cells and bone marrow-
derived cells (BMDCs) recruited to the tumor microenvironment by secreted cyto-
kines play an important role in acquired resistance to anti-VEGF therapies [81].
CAFs entail a large portion of stromal cells present in the tumor environment.
These cells secrete a number of pro-angiogenic mediators, including IGF, FGF,
EGF, cytokines, and chemokines, and are capable of recruiting endothelial progen-
itor cells (EPCs) to the tumor site [93, 94]. Interestingly, Kinugasa et al. showed
that CAFs from anti-VEGF-resistant tumors express high levels of CD44, a marker
for cancer stem cells and cytotoxic resistance. CAFs can hence be considered a
promising target for overcoming resistance to anti-angiogenic agents [95].
BMDCs are comprised of endothelial and pericyte progenitors, macrophages, and
myeloid-derived suppressor cells (MDSCs) [96]. Preclinical models suggest that EPCs
in the tumor microenvironment are able to secrete different proangiogenic factors and
accelerate angiogenesis [97]. More importantly, endothelial precursor cells can
differentiate into endothelial cells and participate in new vessel formation [98, 99].
Tumor-associated macrophages (TAMs) are also involved in angiogenesis.
VEGF blockade by bevacizumab seems to promote TAM proliferation and
reprogramming to pro-angiogenic macrophages [81]. This type of macrophages can
secrete VEGF-A, TNFα, and IL-8, all of which affect different stages of angiogenesis
by modifying the local extracellular matrix, promoting proliferation and migration
of endothelial cells, and inhibiting development of differentiated capillaries [81].
A study by Shojaei et al. demonstrated that MDSCs were present in higher levels
in anti-VEGF-resistant tumors and were functionally different from those in anti-
VEGF-sensitive tumors. This population was able to sustain tumor growth even in
presence of anti-VEGF inhibitors, although the exact mechanism behind this is not
been fully established [100].
CD4+ T-helper cells mediate anti-VEGF resistance through IL-17 production in
the tumor microenvironment and BMDC recruitment. These cells have been shown
to regulate secretion of several proangiogenic factors from CAFs and other stromal
cells. Additionally, Numasaki et al. reported that tumor microvessel density corre-
lates with levels of infiltrating IL-17-producing CD4 T-cells [25, 42, 81, 101].
3.3 Anti-EGFR and -VEGF safety profile
The main side effects of the anti-EGFR therapies cetuximab and panitumumab
are dermatological toxicities, reported in 85–96% of patients (Table 3) [102]. The
most common AE is papulopustular skin rash, generally developing over a period of
6 weeks after starting treatment and potentially impacting quality of life and ther-
apy adherence. General prevention and management principles include the use of
skin moisturizer, sunscreen, hydrocortisone cream, and oral tetracycline. The
STEPP trial compared pre-emptive with reactive skin treatment and showed an
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over 50% reduction in grade ≥ 2 skin toxicities and less QoL impairment with the
pre-emptive compared with reactive treatment [103]. In cases of grade 3 rash,
treatment should be delayed until toxicity has resolved to grade 2 or less and dose
should be reduced in a second occurrence. In grade 1 or 2 rash, dose reduction is not
indicated. Other dermatological symptoms, including hair growth, periungual and
nail plate abnormalities, xerosis, telangiectasias, and pruritus can occur at lower
rates [102].
Infusion reactions commonly occur with cetuximab and should be prevented
with premedication, antihistamines, and corticosteroids. Other adverse effects, like
hypomagnesemia, ocular toxicities as conjunctivitis and blepharitis, and less com-
monly diarrhea, can also occur [104]. Toxicity management is grade-depend and, in
some cases, should be addressed by a multidisciplinary team.
The main anti-VEGF side effects are cardiovascular and kidney problems
(Table 3). Hypertension has been observed at high rates in all phase III studies of
anti-VEGF drugs and is normally manageable with standard antihypertensive
medications, but this treatment should not be initiated in patients with uncontrolled
hypertension. Proteinuria is another side effect, defined as protein content in the
urine >300 mg/dL. No standard treatment is established, but anti-angiogenic drugs
should be disused if protein content in the urine is >2 g/24 h, and evaluation by a
nephrologist should be considered. Hand-foot syndrome is also common with this
class of drugs [105].
Bevacizumab has also been associated with other side effects, like thromboem-





EGFR Rash C 52–89%
P 20–50%
Skin moisturizer, sunscreen,
hydrocortisone cream, and oral
tetracycline
Reduction in 2nd G3
occurrence, delay until ≤
G2








Magnesium replacement Some G3/4 toxicity delay
until recovery
Diarrhea 2% G3/4 Loperamide, hydration,
electrolyte replacement,
hospitalization
Reduction in 1st G3 or 2nd
G2 occurrence






Cease if G4 or persisting
G3 toxicity








Emollient, analgesia Reduction in 1st G3 or 2nd




B 8% Anticoagulation therapy Cease bevacizumab
A, aflibercept; B bevacizumab; C cetuximab; EGFR, epidermal growth factor receptor; G grade; P, panitumumab;
Ram, ramucirumab; Reg, regorafenib, VEGF, vascular endothelial growth factor.
Table 3.
Adverse effects of any severity with anti-EGFR and -VEGF therapies.
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perforation (1.7%). Bevacizumab treatment should be ceased in cases of hemor-
rhagic events ≥grade 3, pulmonary embolism, cerebrovascular events or arterial
insufficiency, arterial thromboembolic events, grade 4 or persistent grade 3
hypertension, nephrotic syndrome, or gastrointestinal perforation [106]. Poten-
tially life-threatening events have occurred only in a small number of patients, with
bevacizumab being well tolerated by the majority.
4. Other targets
4.1 NTRK fusions
The constitutive activation of RTKs promoted by genomic translocations play an
important role in tumorigenesis across different malignancies, including CRC.
Examples include ALK, ROS1, and NTRK1–2-3 (NTRK), which altogether occur in
0.2–2.4% of CRCs and may represent new therapeutic targets (Table 4) [107].
The NTRK (neurotrophic tropomyosin receptor kinase) 1, 2, and 3 genes encode
three tropomyosin receptor kinase (TRK) receptors —TrkA, TrkB, and TrkC—
which are transmembrane proteins [2, 108, 109]. Gene fusions involving those
genes lead to constitutively activated NTRK proteins and, consequently, tumori-
genesis [107]. The prevalence of NTRK fusions in mCRC is estimated to be
0.5–2.0% [110], but increases to 4% in microsatellite instability-high (MSI-H)
mCRC [2].
NTRK gene rearrangements are more commonly detected in non-Lynch syn-
drome MSI-H/ deficient mismatch repair (dMMR) tumors with MLH1 promoter
hypermethylation and wild-type BRAF/KRAS/NRAS, and define a molecular sub-
group associated with poor prognosis [111]. They are also more frequent in elderly
females with right-sided tumors [107, 109, 112].
Fusion-detection options include targeted DNA and RNA panels, RNA sequenc-
ing, FISH, and IHQ [2]. Recent ESMO recommendations for NTRK fusion detection
state that, in tumors with low NTRK fusion frequency, as mCRC, detection can be
done via one-step next-generation sequencing (NGS) or via IHQ followed by NGS
(if IHQ positive) [113].
Larotrectinib and entrectinib are TRK inhibitors approved by the FDA and EMA
in more than 10 tumor types. Larotrectinib, a small-molecule inhibitor targeting all
three TRK proteins, has been tested in the multicenter single-arm LOXO-TRK-
14001, SCOUT, and NAVIGATE clinical trials [111]. Larotrectinib at the dose of
100 mg twice daily showed a good safety profile and good responses (75% of ORR,
1-year PFS of 55%) [114]. In November 2018, the FDA granted accelerated tissue-
agnostic approval to larotrectinib for solid tumors with NTRK gene fusions
[2, 111, 112] Entrectinib is an oral pan-TRK, -ROS1, and -ALK inhibitor that is
clinically active in patients with NTRK-rearranged tumors and is able to penetrate
the blood–brain barrier [107]. Three clinical trials (ALKA-372-001, STARTRK-1,
and STARTRK-2) have investigated this agent [107]. Pooled analyses of the three
trials presented at the ESMO 2018 Congress and ASCO 2019 Meeting showed that
entrectinib induced clinically meaningful durable responses in patients with solid
tumors with or without metastatic central nervous systemic disease harboring
NTRK fusions [111].
The second-generation TRK inhibitor BAY2731954 (formerly known as Loxo-
195) and the next-generation ROS1, pan-TRK, and ALK inhibitor repotrectinib are
being tested, with promising results [111].
As already shown with BRAF V600E mutations, patients with ALK-, ROS-, and
NTRK-rearranged tumors seem to derive no benefit from treatment with anti-
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EGFR monoclonal antibodies [107]. Additionally, the high prevalence of MSI-H
status in rearranged tumors opens the way for evaluation of new combination
approaches including targeted (ALK, ROS1, TrkA-B-C) and immunotherapy
agents [107].
Regarding resistance mechanisms, a dose-dependent effect seems to affect
mutation emergence. Two mutations have been associated with entrectinib resis-
tance: NTRK1 p. G667C and NTRK1 p.G595R [108]. For larotrectinib, three differ-
ent mutational categories have been described: solvent front mutations (NTRK1 p.
G595R, NTRK3 p.G623R); gatekeeper mutations (NTRK1 p.F589L); and xDFG
mutations (NTRK1 p.G667S, NTRK3 p.G696A). Novel agents under development
intend to overcome NTRK1 p.G595R-mediated resistance to TRK inhibitors [115].
4.2 MET alterations
The mesenchymal-epithelial transition (MET) protooncogene (also known as N-
methyl-N0-nitroso-guanidine human osteosarcoma transforming gene) encodes for
c-MET, a receptor with tyrosine kinase activity targeting HGF. Activation of this
pathway has been implicated in CRC metastatic progression [2].
MET receptor tyrosine kinase can be overexpressed in 50–60%, amplified in
10%, and mutated in 5% of CRCs [2]. In a study by Lee et al., c-MET overexpression
showed no correlation with primary tumor site, histological type, or molecular
aberrations, but correlated with shorter OS and was a predictive biomarker of
shorter PFS in bevacizumab-treated patients [3].
EGFR and MET are co-expressed in CRC and MET activation has been implicated
in resistance to the anti-EGFR therapy [2, 116]. Inhibition of the HGF/c-Met pathway
may improve response to EGFR inhibitors in CRC and combination therapy should be
further investigated [116]. This supports the hypothesis that anti-EGFR therapy
selects MET-amplified (cetuximab- and panitumumab-resistant) preexisting clones,
eventually limiting the efficacy of further anti-EGFR therapies [117].
Multiple clinical trials have evaluated MET inhibition, but several of those
conducted in mCRC have been unsuccessful [2]. Treatment strategies targeting
HGF and c-Met include HGF antagonists, c-Met and HGF-blocking antibodies, and
small-molecule c-Met inhibitors [118].
Although MET genomic aberrations are commonly observed in mCRC, these
remain in the research setting [2].
4.3 Other rearrangements
4.3.1 ALK/ROS1 translocations
The EML4-ALK fusion gene is produced by inversion in the short arm of chro-
mosome 2, where anaplastic large-cell lymphoma kinase (ALK) joins echinoderm
microtubule-associated protein-like 4 (EML4), resulting in a chimeric protein with
constitutive ALK activity. ROS1 is an orphan receptor tyrosine kinase phylogeneti-
cally related to ALK [110].
ALK and ROS1 gene rearrangements have not been extensively studied in CRC.
Around 0.8–2.5% of patients with mCRC have been reported to have either ALK or
ROS1 rearrangements [110]. ALK, ROS1, and NTRK fusions occur more frequently
in elderly patients with right-sided, RAS wild-type, MSI-H mCRC, and are associ-
ated with shorter OS and poor prognosis [107, 110]. The small patient numbers
make it challenging to develop a clinical trial of targeted therapies for this patient
population [110]. As no FDA-approved agents targeting these genomic alterations
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Target Frequency Clinicopathological features Testing
methods






0.5–2.0% in mCRC (4% in MSI-H) Associated with MSI-H/dMMR; wt BRAF/
RAS, elderly females and right sided tumors;











ALK/ROS1 0.8–2.5% Associated with MSI-H/dMMR; wt BRAF/
RAS, elderly females and right-sided tumors;






















amplified in 10% and mutated in
5% of CRCs
Shorter OS, shorter PFS with bevacizumab
treatment; poor prognosis; resistance to
anti-EGFR monoclonal antibodies
IHC Clinical trials Under investigation Under
investigation




Vandetanib, cabozantinib Under investigation Under
investigation
dMMR, deficient mismatch repair; FGFR, fibroblast growth factor receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; mCRC, metastatic colorectal cancer; MSI-H, microsatellite
instability-high; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; RT-PCR, reverse transcription polymerase chain reaction; TKI, tyrosine kinase inhibitor; wt, wild-type.
Table 4.















































exist for CRC patients, basket trials (as the TAPUR trial) may give valuable insights
in this setting [112].
4.3.2 RET fusions
RET is a proto-oncogene encoding a transmembrane tyrosine kinase receptor for
the glial-derived neurotrophic factor family [110].
RET fusions occur in 0.2% of solid tumors, being very typical in specific tumor
types, such as thyroid carcinomas [119]. The effect of RET activation is less clear in
CRC, but several studies suggest that it might be associatedwithworse prognosis, poor
treatment response, and reduced OS. Due to rarity of this aberration, clinical trials in
CRC are not easy to conduct, with data derivedmainly from early trials or case reports
[110]. Clinicopathological factors associated with RET fusions include right colon
location, older age, RAS and BRAF wild-type status, andMSI-H status [119].
4.3.3 FGFR
Fibroblast growth factor receptors (FGFRs) are a subfamily of RTKs occurring
in approximately 3–5% of CRC patients [112]. Initial evidence shows poor outcomes
associated with FGFR3 alterations [120]. There is no evidence of clinicopathological
characteristics related to these alterations [120].
Regorafenib, a multi-kinase inhibitor also targeting FGFR, is currently approved
by the FDA for metastatic CRC patients who progressed on frontline therapies. This
agent can be considered in CRC patients with FGFR alterations while novel FGFR
inhibitors are not available [121]. Newly developed, more potent FGFR inhibitors
are currently being investigated in multiple solid tumors [112].
5. Microsatellite instability and immune checkpoints inhibitors
Microsatellite instability (MSI) is currently a key biomarker in CRC, with diag-
nostic, prognostic, and therapeutic implications. For these reasons, MSI analysis is
becoming increasingly important and testing for deficient mismatch repair (d-
MMR)/MSI is recommended, both for hereditary syndrome screening and due to
prognostic and treatment implications [122].
Inactivation of a DNA mismatch repair (MMR) gene (MLH1, MSH2, MSH6, or
PMS2) by mutation or transcriptional silencing results in deficient function of the
MMR system, responsible for excising DNA mismatches introduced by DNA poly-
merase during cell division. This activity loss translates in an accumulation of DNA
replication errors and mismatches in repeated sequences, leading to hypermutated
tumors [123]. In most cases, d-MMR and MSI arise due to sporadic somatic
hypermethylation of MLH1 and other genes, but they can also result from germline
mutations in MMR genes and from Lynch syndrome in approximately 3% of all
CRCs [124].
The MMR system can be assessed through different approaches, as IHC, poly-
merase chain reaction (PCR)-based assays, and more recently NGS. IHC looks at
MLH1, MSH2, MSH6, and PMS2 staining in tumor samples to identify the protein
expression loss that characterizes d-MMR [125]. PCR amplification requires both
tumor and matched normal samples. Five microsatellite loci have been PCR-
amplified and analyzed by capillary electrophoresis. Instability at more than one
locus was defined as MSI-high (MSI-H), at a single locus as MSI-low (MSI-L), and
absence of instability at any locus as microsatellite stable (MSS), proficient MMR
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(p-MMR) [126]. NGS detection directly targets certain genes, which are genome
sequenced to retrieve information on MSI and MMR and tumor mutational burden
(TMB), integrating all information in the same test. NGS requires a smaller sample
and is more accurate than PCR. Ethical issues may arise with the use of this tech-
nique regarding counseling and consent for additional genetic testing [127]. In CRC,
MSI varies according to tumor stage, with higher incidence reported in early stages
(20% in stages I-II, 12% in stage III) and lower incidence reported in the metastatic
setting (4–5%) [128].
5.1 Immune checkpoint inhibitors
The success of immune checkpoint inhibitors (ICI) in d-MMR over the last years
has disclosed a new therapeutic scenario. Endogenous peptides are processed and
presented on major histocompatibility complex (MHC) class I molecules on the
surface of all cells, being recognized by T cell receptors (TCRs). TCR–MHC signaling
pathways are modulated by co-stimulatory or co-inhibitory signals. ICI target co-
inhibitory receptors, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and
programmed cell death 1 (PD-1) on T cells, or their ligands, as programmed cell death
ligand 1 (PDL-1), on tumor and various immune cells [129]. ICI are approved in
several malignancies. In mCRC, phase I trials reported response to immune check-
point therapy in a subgroup of patients with MSI-H, d-MMR, or high TMB [130].
Pembrolizumab is a humanized IgG4 antibody and was the first anti-PD-1 to
show efficacy in d-MMR mCRC (Table 5). In the phase II KEYNOTE-016 trial,
patients with d-MMR tumors responded better to pembrolizumab (RR of 40%,
20-week PFS of 78%) than MSS tumors (RR of 0%, 20-week PFS of 11%) [131].
In the updated analysis, an ORR of 52%, 2-year PFS of 59%, and OS of 72% was
reported for MSI-H CRC [132]. The phase II KEYNOTE-164 trial confirmed the
efficacy of pembrolizumab in second-line setting of MSI-H CRC, with an ORR of
33%, median PFS of 2.3 months, and median OS of 31.4 months [133]. Based on
these results, pembrolizumab was approved by the FDA for MSI-H/d-MMR
unresectable or metastatic CRC after progression on CT. In the phase III KEY-
NOTE-177 trial, first-line treatment with pembrolizumab in monotherapy signifi-
cantly reduced the risk of disease progression or death by 40% (HR 0.60; 95% CI
0.45–0.80; p = 0.0004), with a median PFS of 16.5 months versus 8.2 months with
CT in MSI-H CRC. The study is ongoing, and OS data will be presented later this
year [134]. This led to FDA approval of pembrolizumab in first-line treatment of
unresectable or metastatic MSI-H/dMMR CRC.
Nivolumab, a humanized monoclonal IgG4-based PD-1 antibody, showed activ-
ity in MSI-H/d-MMR refractory CRC in the phase II CheckMate-142 trial, with an
ORR of 31.1% regardless of tumor PD-L1 expression, 1-year PFS of 50%, and OS of
73% [135]. This trial included a cohort of nivolumab in combination with the CTLA-
4 inhibitor ipilimumab, which showed a 55% ORR, 71% PFS, and 85% OS. Both
nivolumab and the combination of nivolumab plus ipilimumab were approved by
the FDA for CT-refractory MSI-H/dMMR mCRC. The immunotherapy doublet was
also evaluated in first line in the CheckMate-142 trial, with 1-year PFS and OS of
77% and 83%, respectively, ORR of 60%, and DCR of 84% [136].
Following these studies, MSI status has become a crucial biomarker to define
therapeutic options for patients in the metastatic setting.
Other PD-1/PD-L1 inhibitors are under investigation, like atezolizumab,
avelumab, and durvalumab, and new immune checkpoint targets are in phase I trials,
such as tumor-overexpressed T cell Ig and mucin domain-containing protein 3
(TIM-3), T cell Ig, and T cell-derived lymphocyte activation gene 3 (LAG-3). [137].
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5.2 Immunotherapy resistance
Most mCRC patients are MSS/p-MMR and results with ICI have been unsatis-
factory, with immune resistance mechanisms not clearly elucidated yet. Several
trials have been developed exploring ways to overcome this resistance, including by
modulating tumor microenvironment, reducing tumor-specific antigen expression,
altering immunosuppressive pathways, and activating other immune checkpoint
pathways, immune regulatory cells, and cytokines [138]. Combining immunother-
apy with CT, radiotherapy, bispecific antibody therapy, other immune checkpoint
modulators, and other targeted agents are among strategies explored. The rationale
behind this multimodal approach is the potential synergistic effect of targeting
different immune escape pathways, resulting in improved response to ICI and
patient outcomes [139].
CT has anti-tumor activity due to the direct cytotoxic effect on cancer cells and to
stimulating host immune response, and several clinical trials are ongoing investigat-
ing the combination of immunotherapy with CT and targeted agents [140]. Radio-
therapy can activate the host immune response by upregulating expression of tumor-
specific neoantigens through cell damage and increasing membrane MHC class I
expression, and several studies are ongoing in CRC combining radiotherapy with ICI.
Another combined strategy is ICI and MEK blockers, considering that MEK blockade
seems to increase T cell response via upregulation of PD-L1 expression [141]. Fol-
lowing a phase Ib trial of atezolizumab and the MEK inhibitor cobimetinib in MSS
CRC, other trials were conducted, with no significant survival improvement [142].
The CEA CD3 TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody
targeting the carcinoembryonic antigen (CEA) on tumor cells and CD3 on T cells,
which displays anti-tumor activity, leading to increased intra-tumoral T cell infiltra-
tion and activation and PD-1/PD-L1 upregulation. CEA-TCB antibody was tested in
phase I trials of MSS CRC plus atezolizumab, showing antitumor activity with
acceptable toxicity [143].
5.3 Biomarkers
Considering immune side effects associated with ICI and their variable efficacy,
it is important to identify biomarkers that help predict response to ICI and select
potentially sensitive patients that can be candidates for these agents.





























60% 77% 83% Not approved
CT, chemotherapy; dMMR, deficient mismatch repair, FDA, Food and Drug Administration; mCRC, metastatic colorectal
cancer; MSI-H, microsatellite instability-high; NR, not reached; OS, overall survival; PFS, progression-free survival; RR,
response rate.
Table 5.
Immune checkpoint inhibitors in mCRC.
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PD-L1 expression level is an established biomarker in some malignancies, but
the relationship between PD-L1 positivity and response has not been proven in CRC
[144]. TMB has emerged as a marker of response to immunotherapy in some
tumors, suggesting that tumor cells with high mutational burden generate and
present more peptide neoantigens on their MHC class I molecules, increasing T cell
infiltration [145]. In CRC, dMMR/MSI-H tumors have a high mutational burden, as
well as some pMMR/MSS, which may present an ultramutated phenotype as DNA
polymerase epsilon (POLE) mutations, found in 1–2% of pMMR CRC. POLE
mutations cause an increased immunogenicity and upregulation of immune check-
point genes, such as PD-1/PD-L1 and CTLA-4, which result in similar clinical
responses to dMMR tumors and may predict response to anti-PD-1 therapy [146].
Some case reports link POLE mutations with efficacy to PD-1 blockade, and phase II
studies are ongoing in this setting.
The interaction between tumor and microenvironment led to the development
of an immunoscore based on calculation of two lymphocytic populations (CD3/
CD45-CD8 or CD8/CD45) in the centre and invasive margins of the tumor, which
may predict ICI response [147]. Other lines of investigation are being explored,
including the study of factors that indicate cytotoxic T cell activity, such as
granzymes, perforins, and IFN-γ levels.
CRC is one of the tumor types for which immunotherapy has been less effective.
Better knowledge of the molecular immune mechanisms is required to develop
predictive biomarkers and effective therapeutic combination strategies, converting
“cold” tumors, immune-desert and immunotherapy-resistant, in “hot” tumors,
inflamed, infiltrated by the immune system, and immunotherapy responsive.
6. Conclusions
CRC treatment has changed over the last decades, not only by including differ-
ent chemotherapy agents and combinations, but mainly because new targeted
agents have emerged.
Inmetastatic setting, anti-EGFR and anti-VEGF drugs are widely used and have
shown gains in survival and response rate, an importantmarker in CRC potentially
resectable liver metastases. In contrast, several trials with targeted agents have been
conducted in the adjuvant setting, without survival benefit. Immunotherapy emerged
as a new treatment optionwith survival benefit, but at themoment it is only effective in
a small portion of patients. Several other agents targeting other pathways are emerging,
such as NTRK, c-MET, ALK, ROS1, and FGFR inhibitors, with promising results.
In conclusion, patients with CRC are living longer with targeted treatments, but
more information about resistance mechanisms and biomarkers is necessary to
extend even more their survival gains.
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